MediWound Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
MediWound (MDWD) Tops Q2 EPS by 35c, Revenues Beat
August 13, 2019 7:02 AM EDTMediWound (NASDAQ: MDWD) reported Q2 EPS of $0.32, $0.35 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $4.45 million.
Business and Financial Highlights for the Second Quarter 2019 and Recent Weeks include:
Total revenues for the second quarter of 2019 were $20.7 million, driven primarily by $17.5 million upfront payment from Vericel for the NexoBrid license; As of June 30, 2019, the Company had $38.7 million in cash and short-term investments, compared to $23.6 million as of December 31, 2018; Entered into an exclusive commercial license and supply agreement with... More